{"createdAt":"7/19/2020, 1:10:32 PM","timestamp":1595178632588,"code":"300244","chineseName":"迪安诊断","market":"SZ","people":[{"id":"迪安诊断技术集团股份有限公司_陈海斌","group":"board","name":"陈海斌","title":"董事长,董事","isMale":true,"age":"51","degree":"本科","salary":"120.0万","stockAmount":"1.936亿","description":"陈海斌先生:1969年出生,中国国籍,无境外永久居留权,本科学历。2001年9月创办了杭州迪安医疗控股有限公司,任董事长兼总经理;2010年5月至今任浙江迪安诊断技术股份有限公司董事长兼总经理,2014年12月起兼任杭州迪安控股有限公司董事长。","lastUpdated":"2017-07-21"},{"id":"迪安诊断技术集团股份有限公司_黄柏兴","group":"board","name":"黄柏兴","title":"董事","isMale":true,"age":"64","degree":"","salary":"120.2万","stockAmount":"420","description":"黄柏兴先生:1956年出生,马来西亚国籍,拥有中国永久居留权。1981年5月至1985年4月任新加坡美国医院公司检验科主任等职;1985年5月至2019年4月任罗氏诊断公司中国区总经理等职。黄柏兴先生于2011年和2013年分别获得上海市政府颁发白玉兰纪念奖和白玉兰荣誉奖;2016年荣获上海市政府颁发的“荣誉市民”称号,同年9月荣获国务院副总理颁发的“中国政府友谊奖”。目前担任公司董事。","lastUpdated":"2019-10-22"},{"id":"迪安诊断技术集团股份有限公司_沈立军","group":"board","name":"沈立军","title":"董事","isMale":true,"age":"51","degree":"硕士","salary":"124.2万","stockAmount":"-","description":"沈立军先生:1969年出生,中国国籍,无境外永久居留权,MBA。曾任太古饮料旗下多家子公司的会计经理、供应链总监、财务行政总监;中粮可口可乐饮料有限公司财务总监,中国食品财务部总经理,中粮可口可乐饮料(新疆)有限公司总经理;贝因美婴童食品股份有限公司副总经理、CFO兼董事会秘书;2017年6月加入迪安诊断技术集团股份有限公司,目前担任公司董事、副总经理。","lastUpdated":"2019-10-22"},{"id":"迪安诊断技术集团股份有限公司_郭三汇","group":"board","name":"郭三汇","title":"董事","isMale":true,"age":"45","degree":"","salary":"135.3万","stockAmount":"-","description":"郭三汇先生:1975年出生,中国国籍,无境外永久居留权。2000年10月至2011年11月任杭州迪安医学检验中心有限公司大区经理、总经理等职;2011年12月至2014年8月任南京迪安医学检验所有限公司总经理;2014年9月至2017年6月任迪安诊断技术集团股份有限公司大区总经理、总裁助理等职;2017年7月至今任迪安诊断技术集团股份有限公司诊断服务事业部总经理,2019年1月21日,任迪安诊断技术集团股份有限公司副总经理。","lastUpdated":"2019-09-27"},{"id":"迪安诊断技术集团股份有限公司_姜傥","group":"board","name":"姜傥","title":"董事","isMale":false,"age":"61","degree":"博士","salary":"90.00万","stockAmount":"-","description":"姜傥女士,1959年出生,中国国籍,无境外永久居留权,博士学历。1988年至2014年9月先后任中山大学附属第一医院肾病实验室主任、肾内科副主任、检验医学部主任、检验系主任;2008年至2010年任美国MDAndersonCancerCenter研究员;2010年10月至2013年12月任浙江迪安诊断技术股份有限公司独立董事;2013年10月至今任广州阳普医疗科技股份有限独立董事;2014年9月起任浙江迪安诊断技术股份有限公司副总经理;2015年1月起任浙江迪安诊断技术股份有限公司副总经理、董事。","lastUpdated":"2017-07-17"},{"id":"迪安诊断技术集团股份有限公司_叶小平","group":"board","name":"叶小平","title":"董事","isMale":true,"age":"57","degree":"博士","salary":"--","stockAmount":"-","description":"叶小平先生,1963年2月出生,中国国籍,无境外永久居留权,英国牛津大学博士学历。多年从事医药临床的研究和管理工作,2005年3月起任职于杭州泰格医药科技股份有限公司,现担任杭州泰格医药科技股份有限公司董事长。","lastUpdated":"2020-03-16"},{"id":"迪安诊断技术集团股份有限公司_陈威如","group":"board","name":"陈威如","title":"独立董事","isMale":true,"age":"50","degree":"","salary":"12.00万","stockAmount":"-","description":"陈威如先生,新加坡国籍,1970年出生,副教授。1996年至1999年任中华经济研究院助理研究员,2003年至2011年人INSEAD欧洲商学院助力教授,2011年至2017年8月任中欧国际工商学院(CEIBS)副教授,2017年8月至今担任菜鸟网络科技有限公司首席战略官,2019年2月至今担任阿里巴巴商学院产业互联网中心主任,兼任好未来教育集团公司、碧桂园服务控股有限公司、房多多网络科技有限公司、迪安诊断技术股份有限公司独立董事。","lastUpdated":"2017-07-17"},{"id":"迪安诊断技术集团股份有限公司_丁国其","group":"board","name":"丁国其","title":"独立董事","isMale":true,"age":"51","degree":"本科","salary":"12.00万","stockAmount":"-","description":"丁国其先生:1969年出生,中国国籍,无其他国家永久居留权,注册会计师,本科学历。1995年5月至2003年6月任上海复星高科技(集团)有限公司财务总监,2002年7月至2007年3月任复地(集团)股份有限公司执行董事,2012年2月至2017年3月任复地(集团)股份有限公司董事,2007年8月至2017年3月任海南矿业股份有限公司董事,2007年8月至2015年6月任上海钢联电子商务有限公司董事,2004年12月至2017年3月历任复星国际有限公司执行董事、高级副总裁和财务总监。","lastUpdated":"2017-07-17"},{"id":"迪安诊断技术集团股份有限公司_蔡江南","group":"board","name":"蔡江南","title":"独立董事","isMale":true,"age":"63","degree":"","salary":"12.00万","stockAmount":"-","description":"蔡江南先生:1957年出生,美国国籍,教授。2006年9月至2006年12月任复旦大学公共经济系主任;1999年4月至2012年4月任美国麻省卫生福利部卫生政策高级研究员;2012年5月至今任中欧国际工商学院卫生管理与政策中心主任;2015年3月至今任和美医疗控股有限公司独立非执行董事;2016年6月至今任上海医药集团股份有限公司独立非执行董事,2017年1月至今任药明康德新药开发有限公司独立非执行董事;现任浙江迪安诊断技术股份有限公司独立董事。","lastUpdated":"2017-07-17"},{"id":"迪安诊断技术集团股份有限公司_程秀丽","group":"supervisoryCommittee","name":"程秀丽","title":"监事会主席","isMale":false,"age":"45","degree":"大专","salary":"62.52万","stockAmount":"-","description":"程秀丽女士,1975年出生,中国国籍,无境外永久居留权,大专学历。2001年历任杭州迪安医疗控股有限公司客服部经理、商务部经理;武汉迪安副总经理。现任浙江迪安诊断技术股份有限公司实验室管理中心副主任、职工代表监事。","lastUpdated":"2017-07-21"},{"id":"迪安诊断技术集团股份有限公司_王荣兴","group":"supervisoryCommittee","name":"王荣兴","title":"监事","isMale":true,"age":"59","degree":"本科","salary":"0.00","stockAmount":"-","description":"王荣兴先生:1961年出生,中国国籍,无境外永久居留权,本科学历,高级会计师。2006年至2009年任浙江复星医药有限公司常务副总经理。现任浙江迪安诊断技术股份有限公司股东代表监事,上海复星医药(集团)股份有限公司财务副总监兼诊断事业部财务总监,上海星佰生物技术有限公司董事。","lastUpdated":"2017-07-17"},{"id":"迪安诊断技术集团股份有限公司_陈世仕","group":"supervisoryCommittee","name":"陈世仕","title":"职工监事","isMale":true,"age":"43","degree":"本科","salary":"54.18万","stockAmount":"-","description":"陈世仕先生,1977年出生,中国国籍,无境外永久居留权,本科学历。2001年历任杭州迪安医疗控股有限公司市场部专员、市场部经理;现任浙江迪安诊断技术股份有限公司市场部经理、职工代表监事。","lastUpdated":"2017-07-01"},{"id":"迪安诊断技术集团股份有限公司_黄柏兴","group":"manager","name":"黄柏兴","title":"总经理","isMale":true,"age":"64","degree":"","salary":"120.2万","stockAmount":"420","description":"黄柏兴先生:1956年出生,马来西亚国籍,拥有中国永久居留权。1981年5月至1985年4月任新加坡美国医院公司检验科主任等职;1985年5月至2019年4月任罗氏诊断公司中国区总经理等职。黄柏兴先生于2011年和2013年分别获得上海市政府颁发白玉兰纪念奖和白玉兰荣誉奖;2016年荣获上海市政府颁发的“荣誉市民”称号,同年9月荣获国务院副总理颁发的“中国政府友谊奖”。目前担任公司董事。","lastUpdated":"2019-10-22"},{"id":"迪安诊断技术集团股份有限公司_沈立军","group":"manager","name":"沈立军","title":"董事会秘书,副总经理","isMale":true,"age":"51","degree":"硕士","salary":"124.2万","stockAmount":"-","description":"沈立军先生:1969年出生,中国国籍,无境外永久居留权,MBA。曾任太古饮料旗下多家子公司的会计经理、供应链总监、财务行政总监;中粮可口可乐饮料有限公司财务总监,中国食品财务部总经理,中粮可口可乐饮料(新疆)有限公司总经理;贝因美婴童食品股份有限公司副总经理、CFO兼董事会秘书;2017年6月加入迪安诊断技术集团股份有限公司,目前担任公司董事、副总经理。","lastUpdated":"2019-10-22"},{"id":"迪安诊断技术集团股份有限公司_郭三汇","group":"manager","name":"郭三汇","title":"副总经理","isMale":true,"age":"45","degree":"","salary":"135.3万","stockAmount":"-","description":"郭三汇先生:1975年出生,中国国籍,无境外永久居留权。2000年10月至2011年11月任杭州迪安医学检验中心有限公司大区经理、总经理等职;2011年12月至2014年8月任南京迪安医学检验所有限公司总经理;2014年9月至2017年6月任迪安诊断技术集团股份有限公司大区总经理、总裁助理等职;2017年7月至今任迪安诊断技术集团股份有限公司诊断服务事业部总经理,2019年1月21日,任迪安诊断技术集团股份有限公司副总经理。","lastUpdated":"2019-09-27"},{"id":"迪安诊断技术集团股份有限公司_王彦肖","group":"manager","name":"王彦肖","title":"副总经理","isMale":false,"age":"39","degree":"硕士","salary":"81.18万","stockAmount":"5.1万","description":"王彦肖女士:1981年出生,中国国籍,无境外永久居留权,浙江大学管理学硕士学历。2006年7月至2017年6月在中信证券股份有限公司投资银行委员会任职,先后任高级经理,副总裁,高级副总裁职务,并取得保荐代表人资格;2017年6月加入浙江迪安诊断技术股份有限公司,2017年7月任浙江迪安诊断技术股份有限公司副总经理职务。","lastUpdated":"2017-07-21"},{"id":"迪安诊断技术集团股份有限公司_侯勇进","group":"manager","name":"侯勇进","title":"副总经理","isMale":true,"age":"47","degree":"本科","salary":"51.64万","stockAmount":"-","description":"侯勇进先生,1973年出生,中国国籍,无境外永久居留权。1996年6月至2004年12月任杭州新亚仪表器材有限公司管理者代表、总经理助理等职;2005年1月至2011年4月任杭州迪安医疗控股有限公司总经理助理等职;2010年5月至2013年12月任迪安诊断技术集团股份有限公司监事会主席;2013年12月至2017年7月担任迪安诊断副总经理;2014年6月至2016年6月任迪安诊断子公司浙江韩诺健康管理有限公司总经理;2016年7月至2018年4月任迪安诊断联营公司杭州全程国际健康医疗中心有限公司总经理等职;2018年5月至今任迪安诊断副总裁,先后分管公司品牌部、行政部、工程管理部等。","lastUpdated":"2019-05-10"},{"id":"迪安诊断技术集团股份有限公司_姚树列","group":"manager","name":"姚树列","title":"副总经理","isMale":true,"age":"53","degree":"","salary":"62.00万","stockAmount":"-","description":"姚树列先生:1967年出生,中国国籍,无境外永久居留权。1987年9月至1998年5月任杭州大华饭店财务经理等职;1998年5月至2016年7月先后任杭州市科技咨询中心主任、杭州市科学技术协会副主席等职;2016年7月至今任迪安诊断技术集团股份有限公司党委书记、副总裁,先后分管研发中心、公共事务部、党工团与科协、基因小镇、健检事业部、司法鉴定事业部、迪安生物等。","lastUpdated":"2019-05-10"},{"id":"迪安诊断技术集团股份有限公司_师玉鹏","group":"manager","name":"师玉鹏","title":"财务总监","isMale":true,"age":"36","degree":"","salary":"39.83万","stockAmount":"-","description":"师玉鹏先生:1984年出生,中国国籍,无境外永久居留权。2006年7月至2011年12月任中国食品酒业单元公司运营分析经理/兼沙城及绍兴工厂财务总监;2012年1月至2013年3月任北京长安创新投资有限公司公司投资经理;2013年4月至2014年12月任中国食品公司运营分析部副总监;2014年12月至2018年8月任中粮长城酒公司财务总监;2018年8月至今任迪安诊断技术集团股份有限公司财务中心总监职务。","lastUpdated":"2019-05-10"}],"companyName":"迪安诊断技术集团股份有限公司","province":"浙江省","englishName":"Dian Diagnostics Group Co Ltd","industry":"医药生物 — 医疗器械Ⅱ","website":"www.dazd.cn","mainBusiness":"医学诊断服务及体外诊断产品销售。","productsName":["诊断服务","诊断产品","冷链物流","健康体检","融资租赁"],"actualController":"陈海斌","actualControllerSharePercentage":"31.20%","registeredCapital":"6.2亿元","employeeAmount":"8794","phone":"86-0571-58085608","location":"浙江省杭州市西湖区科技园金蓬街329号","chineseDescription":"迪安诊断技术集团股份有限公司的主营业务是医学诊断服务及体外诊断产品销售。公司的主要产品及服务是诊断服务、诊断产品、冷链物流、健康体检、融资租赁。在肿瘤学科方面，公司继续深化学科建设与营销力建设并举，于9月在CSCO学术年会摘得了CSCO年会最佳卫星会（基因检测组）第二名的桂冠。已取得三类注册证3项，二类注册证1项，一类备案产品27个，目前有1个三类诊断产品进入注册程序。","foundedDate":"2001-09-05","goPublicDate":"2011-07-19","companyHistory":"","shareholders":[{"organizationId":"","holderName":"陈海斌","totalShare":"2.03亿","sharePercentage":"32.78%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"5188.67万","sharePercentage":"8.36%"},{"organizationId":"00056734","holderName":"中国华融资产管理股份有限公司","totalShare":"3100.78万","sharePercentage":"5.00%"},{"organizationId":"","holderName":"北信瑞丰资产-民生银行-北信瑞丰资产民生民生凤凰1号专项资产管理计划","totalShare":"1710.59万","sharePercentage":"2.76%"},{"organizationId":"T000189763","holderName":"杭州迪安控股有限公司","totalShare":"1404.00万","sharePercentage":"2.26%"},{"organizationId":"","holderName":"高华-汇丰-GOLDMAN,SACHS&CO.LLC","totalShare":"1388.89万","sharePercentage":"2.24%"},{"organizationId":"","holderName":"徐敏","totalShare":"1341.77万","sharePercentage":"2.16%"},{"organizationId":"T000280241","holderName":"中央汇金资产管理有限责任公司","totalShare":"598.50万","sharePercentage":"0.96%"},{"organizationId":"","holderName":"浙江迪安诊断技术股份有限公司-第二期员工持股计划","totalShare":"505.00万","sharePercentage":"0.81%"},{"organizationId":"03148638","holderName":"上海复星平耀投资管理有限公司","totalShare":"501.31万","sharePercentage":"0.81%"}],"englishDescription":"Dian Diagnostics Group Co., Ltd., formely ZHEJIANG DIAN DIAGNOSTICS CO., LTD., is a China-based company principally engaged in the provision of medical diagnosis outsourcing service. The Company operates through two main segments: Service Industry segment and Business Trading segment. The Service Industry segment is primarily involved in the fields including diagnosis services, diagnostic equipment distribution, cold chain logistics and physical health examination, among others. ","englishIndustry":"Healthcare Facilities","Price to earnings (ttm)":"72.94","Price to sales (ttm)":"2.52","Price to book (mrq)":"5.14","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"98.62","Lt debt to equity (mrq)":"24.09","Return on investment (ttm)":"9.38","Return on equity (ttm)":"4.52","Income statement":{"Revenue":"8,453.21","Total revenue":"8,453.21","Cost of revenue, total":"5,735.40","Gross profit":"2,717.81","Selling/general/admin. expenses, total":"1,461.52","Research & development":"189.32","Depreciation/amortization":"57.18","Interest exp.(inc.),net-operating, total":"139.12","Unusual expense (income)":"127.95","Other operating expenses, total":"(31.76)","Total operating expense":"7,678.73","Operating income":"774.48","Other, net":"(3.30)","Net income before taxes":"771.17","Provision for income taxes":"195.61","Net income after taxes":"575.57","Minority interest":"(228.29)","Net income before extra. items":"347.28","Net income":"347.28","Income available to com excl extraord":"347.28","Income available to com incl extraord":"347.28","Diluted net income":"347.28","Diluted weighted average shares":"620.46","Diluted eps excluding extraord items":"0.56","Dps - common stock primary issue":"0.13","Diluted normalized eps":"0.71","Gain (loss) on sale of assets":"(0.13)"},"Balance sheet":{"Cash":"0.24","Cash & equivalents":"1,214.20","Short term investments":"293.24","Cash and short term investments":"1,507.69","Accounts receivable - trade, net":"3,330.08","Total receivables, net":"3,509.97","Total inventory":"1,346.89","Prepaid expenses":"248.11","Other current assets, total":"92.73","Total current assets":"6,705.38","Property/plant/equipment, total - gross":"1,600.14","Accumulated depreciation, total":"(645.23)","Property/plant/equipment, total - net":"954.90","Goodwill, net":"1,693.51","Intangibles, net":"78.64","Long term investments":"877.74","Note receivable - long term":"120.61","Other long term assets, total":"319.24","Total assets":"10,750.01","Accounts payable":"959.04","Accrued expenses":"215.53","Notes payable/short term debt":"1,981.82","Current port. of  lt debt/capital leases":"679.82","Other current liabilities, total":"442.14","Total current liabilities":"4,278.35","Long term debt":"1,063.74","Total long term debt":"1,063.74","Total debt":"3,725.38","Deferred income tax":"11.64","Minority interest":"1,154.39","Other liabilities, total":"258.09","Total liabilities":"6,766.21","Common stock, total":"620.46","Additional paid-in capital":"1,602.33","Retained earnings (accumulated deficit)":"1,761.01","Total equity":"3,983.80","Total liabilities & shareholders' equity":"10,750.01","Total common shares outstanding":"620.46","Tangible book value per share, common eq":"3.56","Treasury stock - common":"0.00"},"Cash flow":{"Cash receipts":"8,789.90","Cash payments":"(5,937.76)","Cash taxes paid":"(441.26)","Changes in working capital":"(1,927.70)","Cash from operating activities":"483.19","Capital expenditures":"(411.50)","Other investing cash flow items, total":"170.19","Cash from investing activities":"(241.31)","Financing cash flow items":"(230.65)","Total cash dividends paid":"(231.83)","Issuance (retirement) of debt, net":"(213.81)","Cash from financing activities":"(676.29)","Foreign exchange effects":"0.57","Net change in cash":"(433.84)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"33.08","52 Week High":"38.66","52 Week Low":"18.79","Pricing date":"","10 Day Average Trading Volume":"15.04","Market Capitalization":"20,524.76","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"235.74","Beta":"1.18","1 Day Price Change":"-0.03","13 Week Price Return (Daily)":"29.47","26 Week Price Return (Daily)":"35.63","5 Day Price Return (Daily)":"-9.89","52 Week Price Return (Daily)":"73.56","Year To Date Price Return (Daily)":"49.48","Month to Date Price Return (Daily)":"-6.29","Price Relative to S&P500 (4 Week)":"-14.59","Price Relative to S&P500 (13 Week)":"3.93","Price Relative to S&P500 (26 Week)":"13.29","Price Relative to S&P500 (52 Week)":"21.15","Price Relative to S&P500 (YTD)":"18.89"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.56","EPS excl. Extra Items (TTM)":"0.45","EPS Normalized (Annual)":"0.71","Revenue per Share (Annual)":"13.62","Revenue per Share (TTM)":"13.14","Book Value (Per Share Annual)":"6.42","Book Value (Per Share Quarterly)":"6.43","Tangible Book Value (Per Share Annual)":"3.56","Tangible Book Value (Per Share Quarterly)":"3.56","Cash Per Share (Per Share Annual)":"2.43","Cash Per Share (Per Share Quarterly)":"2.43","Cash Flow (Per Share Annual)":"1.33","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.13","Dividends (Per Share TTM)":"0.13","EBITD (Per Share TTM)":"1.49","EPS Basic excl. Extra Items (Annual)":"0.56","EPS Basic excl. Extra Items (TTM)":"0.45","EPS incl. Extra Items (Annual)":"0.56","EPS incl. Extra Items (TTM)":"0.45","Free Cash Flow (Per Share TTM)":"-0.21","Dividend (Per Share 5Y)":"0.05"},"Valuation":{"P/E excl. Extra Items (Annual)":"59.10","P/E excl. Extra Items (TTM)":"72.94","P/E Normalized (Annual)":"46.35","Price to sales (Annual)":"2.43","Price to sales (TTM)":"2.52","Price to Tangible Book (Annual)":"9.28","Price to Tangible Book (Quarterly)":"9.28","Price to Free Cash Flow (Per Share Annual)":"--","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"--","Price to Book (Annual)":"5.15","Price to Book (Quarterly)":"5.14","P/E Basic excl. Extra Items (TTM)":"51.75","P/E excl. Extra Items High (TTM)":"150.16","P/E excl. Extra Items Low (TTM)":"23.47","P/E incl. Extra Items (TTM)":"72.94","Net Debt (Interim)":"2,429.63","Net Debt (Annual)":"2,217.70","Dividend Yield (5Y)":"0.20","Dividend Yield":"0.08","Current Dividend Yield (TTM)":"0.39"},"Financial Strength":{"Free Cash Flow (Annual)":"-160.14","Current Ratio (Annual)":"1.57","Net Interest coverage (Annual)":"7.49","Long Term Debt/Equity (Annual)":"26.70","Payout Ratio (Annual)":"22.87","Quick Ratio (Annual)":"1.25","Total Debt/Total Equity (Annual)":"93.51","Current EV/Free Cash Flow (Annual)":"132.81","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.54","Long Term Debt/Equity (Quarterly)":"24.09","Quick Ratio (Quarterly)":"1.24","Total Debt/Total Equity (Quarterly)":"98.62","Free Cash Flow (TTM)":"-132.65","Net Interest Coverage (TTM)":"9.37","Payout Ratio (TTM)":"28.23"},"Margins":{"Gross Margin (Annual)":"32.15","Gross Margin (TTM)":"31.48","Net Profit Margin % (Annual)":"6.81","Net Profit Margin (TTM)":"5.95","Operating Margin (Annual)":"9.16","Operating Margin (TTM)":"7.98","Pretax Margin (TTM)":"7.92","Pretax Margin (Annual)":"9.12","Operating Margin (5Y)":"10.34","Pretax Margin (5Y)":"10.65","Free Operating Cash Flow/Revenue (5Y)":"-4.44","Free Operating Cash Flow/Revenue (TTM)":"-1.63","Gross Margin (5Y)":"32.91","Net Profit Margin (5Y)":"8.22"},"Management Effectiveness":{"Return on Assets (Annual)":"5.38","Return on Equity (TTM)":"4.52","Return on Average Equity (Annual)":"9.07","Return on Average equity (TTM)":"7.28","Return on Investment (Annual)":"11.03","Return on Investment (TTM)":"9.38","Return on Average Assets (5Y)":"6.70","Return on Average Equity (5Y)":"13.39","Return on Investment (5Y)":"12.71","Asset Turnover (Annual)":"0.79","Asset Turnover (TTM)":"0.76","Inventory Turnover (Annual)":"4.52","Inventory Turnover (TTM)":"5.00","Net Income/Employee (Annual)":"67,515.31","Net Income/Employee (TTM)":"55,181.15","Receivables Turnover (Annual)":"2.73","Receivables Turnover (TTM)":"2.44","Revenue/Employee (Annual)":"991,578.60","Revenue/Employee (TTM)":"926,807.10"},"Growth":{"Revenue Growth (Quarterly YoY)":"-16.50","Revenue Growth Rate (5Y)":"44.64","EPS Growth (Quarterly YoY)":"-90.84","EPS Growth (TTM YoY)":"-30.17","EPS Growth Rate (5Y)":"6.16","Dividend Growth Rate (3Y)":"72.35","Revenue Growth (TTM YoY)":"7.34","Revenue Growth (Per Share 5Y)":"37.74","Revenue Growth Rate (3Y)":"30.27","EPS Growth Rate (3Y)":"5.43","Book Value Growth Rate (Per Share 5Y)":"35.20","Tangible Book Value Total Equity CAGR (5Y)":"28.14","Capital Spending growth rate 5 year":"26.82","EBITDA CAGR (5Y)":"38.97","EBITDA Interim CAGR (5Y)":"43.75","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"95.36","Net Profit Margin Growth Rate (5Y)":"-15.01"},"Income Statement":{"Revenue (Annual)":"8,453.21","Revenue (TTM)":"8,150.34","EBITD (Annual)":"1,289.26","EBITD (TTM)":"924.26","Earnings Before Taxes (Annual)":"771.18","Earnings Before Taxes (TTM)":"645.60","Net Income to Common (Annual)":"347.28","Net Income to Common (TTM)":"281.36","Earnings Before Taxes Normalized (Annual)":"899.12","Net Income Available to Common Normalized (Annual)":"442.78","Diluted Normalized EPS excl. Extra Items (TTM)":"0.58"}}}